OBJECTIVE:To evaluate the efficacy and safetyof ribavirin for infantile rotavirus enteritis.METHODS:Between May 2012 and April 2014, a total of 164 children with rotavirus enteritis in our hospital were randomized to either treatment group or control group of 82 cases each.The patients in the treatment group were treated with ribavirin while those in the control group were treated with conventional therapy.RESUTLS:The total response rate in the treatment group was significantly higher than in the control group[91.5%(75/82) vs.73.2%(60/82);P<0.05] and the treatment cost, the incidence of enteritis, the cure time of enteritis and the incidence of adverse drug reactions in the treatment group were also significantly higher than in the control group(P<0.05).CONCLUSIONS:Ribavirin was proved to be a feasible, safe and effective therapy for infantile rotavirus enteritis, thus its use is worth of clinical recommendation.%目的：观察利巴韦林治疗婴幼儿轮状病毒肠炎的临床疗效与安全性。方法：选择2012年5月—2014年4月接受治疗的164例轮状病毒肠炎患儿作为研究对象，采用随机数字法分成对照组和治疗组各82例，其中治疗组患儿采用利巴韦林治疗，对照组患儿采用常规方法治疗。结果：治疗组患儿的临床总有效率为91.5％（75／82），对照组为73.2％（60／82），治疗组患儿的临床疗效明显好于对照组，差异有统计学意义（ P＜0.05）。同时，治疗组患儿的治疗费用、肠炎发生率、肠炎痊愈时间以及不良反应发生率等临床指标均明显优于对照组，差异有统计学意义（P＜0.05）。结论：应用利巴韦林对婴幼儿轮状病毒肠炎进行治疗，可以有效解除患儿的临床症状，是一种可行性、安全性、有效性较高的治疗方案，值得在临床中广泛推广应用。
展开▼
